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Abstract
Background: Xenotransplantation holds the promise of providing an unlimited supply of donor organs for terminal patients
with organ failure. Pre-existing natural antibodies to the Galα1,3Galβ1,4GlcNac-R (αGal) carbohydrate xenoantigen, however,
bind rapidly to the graft endothelium and initiate hyperacute rejection of wild type pig grafts in humans. Experimental procedures
designed to prevent xenoantibody-mediated rejection have been tested in gal knockout mice. These mice produce anti-gal
xenoantibodies and are widely used as small animal models for xenotransplantation research. In this model, chimerism for cells
expressing the gal carbohydrate can be achieved by transplantation of mixed cells or by transduction of bone marrow cells with
viral vectors expressing a functional α1,3 galactosyltransferase gene. Chimerism induces tolerance to heart grafts expressing
αGal. The mechanisms by which tolerance is achieved include systemic changes such as clonal deletion and/or anergy. Intragraft
changes that occur during the early stages of tolerance induction have not been characterized.
Results: Cytoprotective genes heme oxygenase-1 (HO-1), Bcl2, and A20 that have been reported to contribute to long-term
graft survival in various models of accommodation were not expressed at high levels in tolerant heart grafts. Intragraft gene
expression at both early (Day 10) and late (>2 month) time points after heart transplant were examined by real-time PCR and
microarray analysis was used to identify changes associated with the induction of tolerance. Intragraft gene expression profiling
using microarray analysis demonstrated that genes identified in the functional categories of stress and immunity and signal
transduction were significantly up-regulated in early tolerant grafts compared with syngeneic control grafts. Biological process
classification showed lower binomial p-values in the categories of "response to biotic stimulus, defense response, and immune
response" suggesting that up-regulated genes identified in these grafts promote survival in the presence of an immune response.
The expression of the incompatible carbohydrate antigen (αGal) was reduced by 2 months post-transplant when compared with
the expression of this gene at Day 10 post-transplant. These results suggest that the gal carbohydrate antigen is downmodulated
over time in grafts that demonstrate tolerance.
Conclusion: Our study suggests that tolerance is associated with intragraft gene expression changes that render the heart
resistant to immune-mediated rejection. Genes associated with stress and immunity are up-regulated, however cytoprotective
genes HO-1, Bcl2 and A20 were not up-regulated. The expression of the gal carbohydrate, the key target initiating an immune
response in this model, is down-regulated in the post-transplant period.
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Background
The use of pigs as organ donors could potentially provide
an unlimited supply of organs for patients with end-stage
organ failure. The Galα1,3Galβ1,4GlcNac-R (αGal) car-
bohydrate expressed on wild type pig organs, however,
initiates the rapid rejection of these grafts [1]. The α1,3
galactosyltransferase (GalT) knockout model (GalT-/-) in
mice provides a unique system in which to study the
immunological events associated with the rejection of
cells or organs expressing the gal carbohydrate [2]. Several
promising therapies designed to prevent graft rejection
have been studied in this model, including the induction
of chimerism to achieve transplant tolerance [3]. Mixed
chimerism, acquired by transplantation of the donor's
bone marrow cells into the recipient, results in tolerance
to xenoreactive T cells as well as B cells [4]. Molecular chi-
merism, acquired by transplantation of transduced, autol-
ogous cells expressing a new gene has also been
successfully applied to achieve tolerance [5]. Our group
has focused on the use of gene therapy using lentiviral vec-
tors to express the porcine α1,3 galactosyltransferase gene
and establish a state of chimerism as a means of achieving
transplant tolerance [6-8]. Irrespective of the methodol-
ogy applied to establish chimerism prior to transplanta-
tion, receptor editing and/or clonal deletion play a role in
the induction of tolerance [7,9,10]. In accommodation
models, in which a transplanted organ may survive con-
tinuously in the presence of anti-graft antibodies and
complement that might otherwise cause rejection, sys-
temic events as well as intragraft gene expression changes
have been shown to contribute to prolonged graft survival
[11]. Cytoprotective genes are induced during accommo-
dation and protect the grafts by blocking the activation of
nuclear factor kappa B (NF-κB) and preventing apoptosis
[12,13]. Intragraft gene expression changes associated
with the induction of transplant tolerance are less well-
characterized and may differ between models [14-18].
The development of gene expression profiling using
microarrays has now provided a technologically sophisti-
cated means of studying intragraft gene expression pro-
files in tolerant and/or rejected grafts [19-25].
Identification of distinct patterns of gene expression
changes in graft biopsies may be useful in predicting graft
outcome.
In this manuscript, early intragraft gene expression
changes associated with the induction of chimerism and
tolerance are identified. We demonstrate that expression
of cytoprotective genes, heme oxygenase-1 (HO-1), Bcl2,
and A20, do not play a role in tolerance induction in this
model. This new information can be used to compare
early gene expression profiles associated with various
models of tolerance induction with the goal of identifying
common intragraft gene expression changes that promote
graft survival.
Results
The level of GalT expression in transduced bone marrow 
cells
Sublethally irradiated GalT-/- mice transplanted with trans-
duced bone marrow expressing GalT prior to heart trans-
plantation demonstrated chimerism and permanently
accepted heart grafts from wild type mice, consistent with
data previously reported from our laboratory [7]. The level
of GalT transduction in bone marrow cells was examined
by real-time PCR using primers that specifically identify
the galactosyltransferase gene in the lentiviral vector con-
struct. The newly-introduced galactosyltransferase gene
was expressed in transduced bone marrow cells in vitro as
well as in vivo in bone marrow cells isolated from GalT-/-
mice at fourteen days post-GalT bone marrow transplanta-
tion (BMT) as identified by real-time PCR (Fig. 1).
Cytoprotective genes
Genes such as heme oxygenase-1 (HO-1; Hmox1, Hsp32),
Bcl2, and A20 (Tnfaip3) have been associated with
accommodation in rodent xenograft models [11-13]. In
contrast, gene expression changes studied in biopsies of
accommodated kidney allografts in humans failed to
demonstrate significant changes in the expression levels
of the same cytoprotective genes [26]. To investigate
whether cytoprotective genes are expressed in tolerant
grafts in our model, we compared the expression levels of
HO-1, Bcl2 and A20 by real-time PCR in transplanted tol-
erant and syngeneic control hearts. Total RNA was iso-
lated from grafts at day 10 post-heart transplantation. The
selection of this time point allowed us to study gene
expression changes that occur in graft hearts at the early
Level of GalT transduction in bone marrow cells Figure 1
Level of GalT transduction in bone marrow cells. 
GalT is not expressed in the bone marrow cells of the nor-
mal GalT-/- mouse, however, transduced bone marrow cells 
in vitro and bone marrow cells from GalT BMT mice at day 14 
post-BMT express the galactosyltransferase gene as identified 
by real-time PCR. Relative cDNA expression levels were 
normalized with respect to GAPDH gene expression as an 
internal control. The samples were run in triplicate and the 
experiment was repeated twice. Standard deviations are 
shown for each experiment.
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stages of tolerance induction. We also isolated total RNA
from grafts in GalT BMT chimeras demonstrating long-
term tolerance to αGal+ heart grafts during later stages of
tolerance (>2 months post-heart transplantation) to allow
us to compare levels of cytoprotective gene expression at
early and later time points. Lymphocyte infiltration that
was evident in rejecting grafts could not be detected in tol-
erant hearts as identified by histology at both early and
late time points after transplantation. Infiltrating immune
cells were therefore not likely to contribute substantially
to gene expression changes in the tolerance model. Our
results show that cytoprotective genes were not increased
at either early or late time points in tolerant grafts (Fig.
2a–c). These data suggest that the mechanism of tolerance
in this model does not involve selective up-regulation of
these genes.
Gene expression profiling in tolerant heart grafts: 
Functional classification of significantly up-regulated 
genes
In order to further understand the early events that occur
within tolerant grafts, we extended our analysis to the
application of gene expression profiling. This technique
makes it possible to identify novel gene expression
changes that characterize the immunological events asso-
ciated with tolerance induction. We isolated RNA from
transplanted hearts following GalT BMT at ten days after
heart transplantation (n = 4) as well as from syngeneic
heart transplant controls (n = 4) for microarray analysis.
Our objective was to identify novel genes and pathways
that may be associated with the early stages of tolerance
induction and to compare our data with information in
the literature identifying genes uniquely expressed in tol-
erant grafts. The data were normalized with the dChip
software and analyzed by the algorithm "Significant Anal-
ysis of Microarrays (SAM)" with a q-value cutoff of 10%
and a fold change of greater than 1.5 and less than 0.75.
Using these criteria, 535 probe sets representing 465 genes
were selected as up-regulated genes and 311 probe sets
representing 272 genes were selected as down-regulated.
In order to determine whether these genes could be asso-
ciated with specific functional categories, we used L2L
software (ver. 2006.2) to sort the data into each of 9 func-
tional subsets according to the Gene Ontology (GO; ver.
2006.2) "biological process" categories (Fig. 3). The genes
classified in the subsets of "stress and immunity" (GO:
0006955, 0006350), "transcription/RNA processing"
(GO: 0007165), and "signal transduction" (GO:
0016070, 0006350) were significantly up-regulated dur-
ing the early stages of tolerance induction. Genes classi-
fied in the "energy metabolism" (GO: 0005975, 0006118,
0006629, 0006119, 0006800) category were down-regu-
lated.
Profiling of the biological processes associated with 
significantly up-regulated genes induced in tolerant heart 
grafts
L2L software was used to sort and prepare a summary pro-
file of biological processes associated with genes with
increased expression in tolerant grafts as compared to
controls at the day 10 time point (Table 1). This table sep-
arates genes according to biological processes using a p-
value of less than 0.01 as a basis for selection. Genes are
ranked according to "binomial p-values," the p-values
representing the statistical significance of the overlap,
derived from a binomial distribution. "Total probes" sig-
nifies the total number of probes representing genes on
the list. The list of "expected matches" includes the
number of probes derived from the list that would match
our data by random chance. The list of "actual matches"
shows the number of matches identified with our data.
"Fold enrichment" is the fold-enrichment of genes that
match our data (actual/expected). As shown in Table 1,
the top three categories for function of genes with
increased expression in tolerant hearts were "response to
biotic stimulus", "defense response" and "immune
response." Gene Ontology defines "response to biotic
stimulus" as a change in state or activity of a cell or an
organism (in terms of movement, secretion, enzyme pro-
duction, gene expression, etc.) as a result of a biotic stim-
ulus, a stimulus caused or produced by a living organism.
The genes in this category show a 2.7 fold enrichment, the
highest number of actual matches, and the lowest bino-
mial p-values. Genes in the "defense response" and
"immune response" categories demonstrated similar lev-
els of fold enrichment, actual matches and low binomial
p-values. Within these 3 categories, fifty-five up-regulated
genes that were common to all three categories were iden-
tified as preferentially expressed during the early stages of
tolerance induction in our model (Table 2).
Intragraft α1,3 galactosyltransferase gene expression
An additional factor that plays a key role in long-term
graft survival is the level of expression of xenoantigens on
the surface of the graft. Accommodation has been associ-
ated with a decrease in the expression level of incompati-
ble carbohydrate antigens on highly vascularized grafts
exposed to tolerable levels of allo- or xenoantibodies [27].
We therefore evaluated whether or not changes in expres-
sion level of the gene encoding for the gal carbohydrate
occur in either the immediate or late post-transplant peri-
ods in our model of tolerance induction. Expression of the
galactosyltransferase gene which encodes the target of
rejection of wild type organs in this model was signifi-
cantly reduced during the late post-transplant period (Fig.
4), suggesting that a reduction in the level of expression of
the αGal epitope occurs on the graft at later time points
post transplant. Lower levels of expression of the gal car-BMC Immunology 2008, 9:5 http://www.biomedcentral.com/1471-2172/9/5
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bohydrate may therefore contribute to the maintenance of
long-term tolerance in this model.
Validation of microarray results by real-time PCR
Real-time PCR was used to confirm the results obtained
from the gene expression profiling studies. Four up-regu-
lated genes and 3 down-regulated genes were selected for
quantification of gene expression by real-time PCR. RNA
from transplanted hearts isolated from GalT BMT groups
(n = 4) and syngeneic control groups (n = 4) was used for
this experiment. Real-time PCR results were found to cor-
relate with the differential gene expression data obtained
by the microarray analysis (Fig. 5). The sequences of prim-
ers used for real-time PCR validation are listed in Table 3.
Discussion
An understanding of the systemic and intragraft gene
expression changes that promote immune modulation
and long term graft survival may provide insight into new
ways to achieve tolerance. One of the most well-studied
methods for inducing tolerance is by the induction of chi-
merism in Gal KO mice [3-7]. These mice do not express
the galactosyltransferase that is responsible for gal carbo-
hydrate expression and produce high levels of anti-gal
antibodies after immunization [28]. As gal knockout mice
age, they naturally produce anti-α Gal antibodies at levels
that are sufficient to cause delayed rejection of wild type
mouse hearts [29]. Anti-gal xenoantibodies induced after
immunization are capable of initiating hyperacute rejec-
tion of gal+ hearts [28]. This small animal model is exten-
sively used to study xenoantibodies to grafts that express
the gal carbohydrate, the major antigen responsible for
initiating xenograft rejection. Chimerism for the gal car-
bohydrate can be achieved in a number of ways and
results in tolerance to wild type gal+ heart grafts [3-7].
Functional subsets that are up- or down-regulated in toler- ance model Figure 3
Functional subsets that are up- or down-regulated in 
tolerance model. L2L software was used to sort the up- or 
down-regulated genes in tolerant grafts (GalT BMT) com-
pared to syngeneic control grafts. Nine functional subsets 
were identified using Gene Ontology Biological Process cate-
gories.
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Cytoprotective gene expression by real-time PCR Figure 2
Cytoprotective gene expression by real-time PCR. 
Cytoprotective genes (Hmox1, Bcl2, Tnfaip3) expressed in 
syngeneic control grafts and in tolerant grafts at both early 
(day 10) and late (>2 months) time points after transplanta-
tion were identified by real-time PCR. Relative cDNA 
expression levels were normalized with respect to GAPDH 
gene expression as an internal control. Results are shown as 
the logarithmic value of respective gene expression. Standard 
deviations are shown for each experiment which was run in 
triplicate. (a): Hmox1 (HO-1); (b): Bcl2; (c): Tnfaip3 (A20).
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Table 1: Gene Ontology: biological process – up-regulated genes in tolerant hearts compared to syngeneic controls
List Name Total probes Expected matches Actual matches Fold Enrichment Binomial p-values
response to biotic stimulus 1353 22.64 61 2.69 1.16E-11
defense response 1275 21.33 53 2.48 3.86E-09
immune response 1166 19.51 50 2.56 3.87E-09
response to virus 108 1.81 12 6.64 3.04E-07
response to pest, pathogen or parasite 767 12.83 33 2.57 1.41E-06
response to other organism 782 13.08 33 2.52 2.13E-06
response to stimulus 3134 52.44 87 1.66 6.47E-06
JAK-STAT cascade 66 1.1 8 7.24 1.49E-05
protein kinase cascade 610 10.21 26 2.55 2.02E-05
response to pathogenic bacteria 24 0.4 5 12.45 4.27E-05
regulation of DNA binding 15 0.25 4 15.94 9.23E-05
I-kappaB kinase/NF-kappaB cascade 223 3.73 13 3.48 1.18E-04
nuclear transport 254 4.25 14 3.29 1.19E-04
nucleocytoplasmic transport 276 4.62 14 3.03 2.79E-04
response to pathogen 35 0.59 5 8.54 2.80E-04
maintenance of localization 38 0.64 5 7.86 4.15E-04
response to bacteria 59 0.99 6 6.08 4.63E-04
regulation of binding 23 0.38 4 10.39 5.38E-04
response to stress 1778 29.75 49 1.65 6.71E-04
T cell receptor signaling pathway 14 0.23 3 12.81 1.48E-03
immune cell mediated cytotoxicity 15 0.25 3 11.95 1.83E-03
negative regulation of protein import into 
nucleus
15 0.25 3 11.95 1.83E-03
negative regulation of transcription factor 
import into nucleus
15 0.25 3 11.95 1.83E-03
cytoplasmic sequestering of transcription 
factor
15 0.25 3 11.95 1.83E-03
cytoplasmic sequestering of protein 15 0.25 3 11.95 1.83E-03
negative regulation of nucleocytoplasmic 
transport
16 0.27 3 11.21 2.23E-03
negative regulation of protein transport 16 0.27 3 11.21 2.23E-03
inflammatory response 311 5.2 13 2.5 2.57E-03
cholesterol metabolism 140 2.34 8 3.42 2.61E-03
tyrosine phosphorylation of STAT 
protein
17 0.28 3 10.55 2.67E-03
regulation of NF-kappaB import into 
nucleus
17 0.28 3 10.55 2.67E-03
NF-kappaB import into nucleus 17 0.28 3 10.55 2.67E-03
antigen receptor-mediated signaling 
pathway
18 0.3 3 9.96 3.17E-03
nuclear export 115 1.92 7 3.64 3.34E-03
cell killing 19 0.32 3 9.44 3.71E-03
sterol metabolism 149 2.49 8 3.21 3.82E-03
detection of stimulus 63 1.05 5 4.74 4.12E-03
positive regulation of apoptosis 368 6.16 14 2.27 4.18E-03
positive regulation of programmed cell 
death
368 6.16 14 2.27 4.18E-03
detection of external stimulus 41 0.69 4 5.83 4.85E-03
detection of abiotic stimulus 41 0.69 4 5.83 4.85E-03
DNA metabolism 1205 20.16 33 1.64 4.94E-03
viral genome replication 42 0.7 4 5.69 5.29E-03
RNA export from nucleus 97 1.62 6 3.7 5.94E-03
nucleic acid transport 97 1.62 6 3.7 5.94E-03
RNA transport 97 1.62 6 3.7 5.94E-03
establishment of RNA localization 97 1.62 6 3.7 5.94E-03
caspase activation 44 0.74 4 5.43 6.25E-03
response to drug 44 0.74 4 5.43 6.25E-03
positive regulation of caspase activity 44 0.74 4 5.43 6.25E-03
lipid transport 131 2.19 7 3.19 6.78E-03
RNA localization 101 1.69 6 3.55 7.20E-03BMC Immunology 2008, 9:5 http://www.biomedcentral.com/1471-2172/9/5
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Table 2: Up-regulated genes in tolerant hearts classified as response to biotic stimulus, defense response, and immune response
Probe ID Gene Symbol Gene Title Also known as
1416111_at Cd83 CD83 antigen
1416295_a_at Il2rg interleukin 2 receptor, gamma chain CD132
1416697_at Dpp4 dipeptidylpeptidase 4 Cd26; THAM; Dpp-4
1459973_x_at Dpp4
1417056_at Psme1 proteasome (prosome, macropain) 28 subunit, 
alpha
PA28a
1417189_at Psme2 proteasome (prosome, macropain) 28 subunit, 
beta
PA28b
1417640_at Cd79b CD79B antigen B29; Igb; Ig-beta
1418652_at Cxcl9 chemokine (C-X-C motif) ligand 9 CMK; Mig; Scyb9; crg-10
1419282_at Ccl12 chemokine (C-C motif) ligand 12 MCP-5; Scya12
1419684_at Ccl8 chemokine (C-C motif) ligand 8 HC14; MCP-2; Scya8
1420089_at Nfkbia nuclear factor of kappa light chain gene 
enhancer in B-cells inhibitor, alpha
1448306_at Nfkbia
1449731_s_at Nfkbia
1420788_at Klrg1 killer cell lectin-like receptor subfamily G, 
member 1
MAFA; 2F1-Ag; MAFA-L
1420915_at Stat1 signal transducer and activator of transcription 1
1450033_a_at Stat1
1450034_at Stat1
1421578_at Ccl4 chemokine (C-C motif) ligand 4 Act-2; Mip1b; Scya4; MIP-1B
1421818_at Bcl6 B-cell leukemia/lymphoma 6 Bcl5
1421911_at Stat2 signal transducer and activator of transcription 2
1422005_at Eif2ak2 eukaryotic translation initiation factor 2-alpha 
kinase 2
Pkr; tik; Prkr
1422028_a_at Ets1 E26 avian leukemia oncogene 1, 5' domain Tpl1; Ets-1
1422903_at Ly86 lymphocyte antigen 86 MD1
1422962_a_at Psmb8 proteosome (prosome, macropain) subunit, beta 
type 8 (large multifunctional peptidase 7)
Lmp7
1424208_at Ptger4 prostaglandin E receptor 4 (subtype EP4) EP4; Ptgerep4
1425396_a_at Lck lymphocyte protein tyrosine kinase Hck-3; p56
1425548_a_at Lst1 leukocyte specific transcript 1 B144
1426587_a_at Stat3 signal transducer and activator of transcription 3 Aprf
1427689_a_at Tnip1 TNFAIP3 interacting protein 1 Nef; ABIN; Naf; ABIN1
1427746_x_at H2-K1 histocompatibility 2, K1, K region H-2K; H2-K; MHC I;
1429272_a_at Apol3 apolipoprotein L 3
1433508_at Klf6 Kruppel-like factor 6 FM2; FM6; Zf9; BCD1; CPBP; Copcb; 
Ierepo1; Ierepo3
1434438_at Samhd1 SAM domain and HD domain, 1 Mg11
1435560_at Itgal integrin alpha L Cd11a; LFA-1; Ly-15; Ly-21
1435710_at Cd226 CD226 antigen Pta1; PNAM1; TLiSA1
1435906_x_at Gbp2 guanylate nucleotide binding protein 2
1436562_at Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 RIG-I
1436779_at Cybb cytochrome b-245, beta polypeptide Cgd; Nox2; gp91phox
1437304_at Cblb Casitas B-lineage lymphoma b
1438052_at Ptprc protein tyrosine phosphatase, receptor type, C Ioc; Ly-5; T200; CD45R; Lyt-4
1439034_at Spn sialophorin Cd43; Ly48; Galgp
1439680_at Tnfsf10 tumor necrosis factor (ligand) superfamily, 
member 10
TL2; Ly81; Trail; APO-2L
1439773_at Ly6e lymphocyte antigen 6 complex, locus E Ly67; Tsa1; RIG-E; Sca-2; TSA-1
1439819_at Ctsc cathepsin C DPP1
1440169_x_at Ifnar2 interferon (alpha and beta) receptor 2
1441026_at Parp4 poly (ADP-ribose) polymerase family, member 4 PH5P; p193; Gm743; PARPL; VPARP; 
VAULT3; Adprtl1
1445897_s_at Ifi35 interferon-induced protein 35 IFP35
1459151_x_at Ifi35
1448436_a_at Irf1 interferon regulatory factor 1BMC Immunology 2008, 9:5 http://www.biomedcentral.com/1471-2172/9/5
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Table 3: Primer sequences used to identify gene transcript levels by real-time PCR
Gene Symbol Sequence (5' -> 3')
lenti-porcine GalT sense GTT CGC TTC TCG CTT CTG TT
antisense CCA AAA CAC AAC CAT TAC AGT TGA G
Ptger4 (EP4) sense TAC TTC TAC AGC CAC TAC GTG GAC
antisense TGG TCC AGT CGA TGA AGC ACC AGG
Tnfsf10 (Trail) sense ACC ACG TGC TCT TTA GGA ATG GAG
antisense AGA CCA TCT TGG AAG CGT CTT CAG
Il2rg (CD132) sense GGT TGG AAC GAA TGC CTC CAA TTC
antisense GCA GAA CCG TTC ACT GTA GTC TGG
Stat3 sense GCA AAG AGT CAC ATG CCA CGT TGG
antisense AGA TAC CTG CTC TGC AGA AAC TGC
Cfh sense AAG GTG GCA GTC ATT ACC TCG CTG
antisense GTT CAT GAC TGC TGG ACT CAA TGG
Cxcl12 sense CGC TCT GCA TCA GTG ACG GTA AAC
antisense CTT CAG CCG TGC AAC AAT CTG AAG
Hfe sense TCT CTA AGG TGT CAG GCT CTG GAC
antisense TGT CAG CCA GCC TTG ATA GGT CTC
Foxp3 sense TCC AGA GAG AAG TGG TGC AGT CTC
antisense GTG GCT ACG ATG CAG CAA GAG CTC
Hmox1 (HO-1) sense ACA GAT GGC GTC ACT TCG TCA GAG
antisense ACT GCC ACT GTT GCC AAC AGG AAG
Bcl2 sense GAT GCC TTT GTG GAA CTA TAT GGC
antisense AGG TAT GCA CCC AGA GTG ATG CAG
Tnfaip3 (A20) sense CTA AGC CAA CGA GTA GGT TCT GTG
antisense CCA TAC ATC TGC TTG AAC TGG TAG
GAPDH sense GGC ATG GAC TGT GGT CAT GAG
antisense TGC ACC ACC AAC TGC TTA GCC
Intragraft GalT expression changes in tolerant heart grafts Figure 4
Intragraft GalT expression changes in tolerant heart 
grafts. Ggta1 (1418483_a_at) probe expression levels at 
early (day 10) and late (>2 months) time points in tolerant 
hearts, identified by microarray analysis. Standard deviations 
are shown as error bars.
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Validation of microarray results by real-time PCR. 
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Hfe) in the early tolerance group (GalT BMT) compared to 
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mine whether the data obtained by microarray analysis could 
be validated using an alternative technique. Relative cDNA 
expression levels were normalized with respect to GAPDH 
gene expression as internal control. Results are shown as the 
logarithmic value of mean fold-change of gene expression.
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The mechanisms by which tolerance can be achieved after
the induction of chimerism include systemic changes such
as B cell hyporesponsiveness, initially due to anergy, and
receptor editing or clonal deletion which occur later [9].
Regulatory T cells can also contribute to long-term graft
survival [30]. Our laboratory has been interested in stud-
ying the induction of chimerism using lentiviral vectors to
express the galactosyltransferase gene in the bone marrow.
In this model, systemic events associated with tolerance
induction similarly include receptor editing and/or clonal
deletion [7]. Cytoprotective IgG2b antibodies [7] and ele-
vated levels of cytoprotective genes HO-1 and A20 that
contribute to graft accommodation [11,31] were not
induced at levels higher than those identified in syngeneic
transplant controls [21]. Data similar to ours was recently
reported in a clinical study which showed that protective
genes Bcl-2 and A20 were not induced in human cardiac
biopsies taken at 0–2 months from non-rejecting grafts,
however these genes were shown to be induced at later
times (>10 months post-transplant) [32]. The time
between transplantation and gene expression analysis
may therefore be an important consideration. Cytoprotec-
tive genes were, however, induced at early timepoints in
the rejecting grafts in our study. This finding is consistent
with prior reports that A20 and/or HO-1 are upregulated
in response to immune injury during acute rejection of
renal, heart and lung allografts [32-34]. These gene prod-
ucts have anti-inflammatory and anti-apoptotic functions
which may be produced in an attempt to protect grafts
from injury [35-37]. Expression of the gene encoding the
gal carbohydrate, in contrast, was significantly reduced in
tolerant hearts. Similar findings have been reported in
models of accommodation where expression of endothe-
lial carbohydrate antigens declines post-transplantation
[27]. The level of expression of the gal carbohydrate influ-
ences not only the antibody response, but impacts the cel-
lular immune response. NK cells have receptors that
recognize the α Gal epitope, and this recognition may
contribute to the induction of a cellular immune response
in the post-transplant period [38,39].
The gene expression profile associated with tolerance
induction may be a key predictor of graft outcome. Within
the past few years, microarray technology has been
applied to identify gene expression changes that distin-
guish tolerance and rejection in various models. Although
the conditions under which tolerance is induced are not
uniform, the source of cells or tissues varies, the biostatis-
tical analysis differs and the software used in studies from
other laboratories varies, differential gene expression in
stress-activated pathways and immune response genes
tends to distinguish tolerant grafts from controls
[21,22,40-43]. Our results are strikingly similar to those
reported from two other laboratories who identified a
small number of genes that were associated with the
induction and maintenance of tolerance to liver grafts in
rodents. The genes that were common to the molecular
signature of tolerance in these three studies included
STAT-1, IRF-1, Gpb2 and several chemokines [42,43].
STAT-1 and IRF-1 are the two key transcripts that play a
role in the pathway that links IFN-γ signalling to the
induction of apoptosis [44,45]. The fact that these tran-
scripts were induced in the early stages of tolerance to
heart and liver grafts [42] and in the PBL of tolerant recip-
ients of liver grafts at 100 days post-transplantation [43]
suggests that the STAT-1/IRF-1 apoptotic pathway may be
important in the induction and maintenance of graft tol-
erance. The data from our lab and others suggests that the
tolerant graft itself responds on a continuous basis to the
environment around it.
Tolerance to pig organs is a long-term goal in the field of
xenotransplantation. Whether this is achieved by intro-
duction of new genes in the donor organs prior to trans-
plantation, or by the development of methods that
adequately suppress the immune response to porcine
xenoantigens, gene expression profiling of tolerant grafts
is providing new insight into the mechanisms by which
tolerance is achieved and maintained. An improved
understanding of the similarities and differences in intra-
graft gene expression profiles that are associated with tol-
erance induced by various approaches and a clear
statement of the methods used for the analysis of the data
should allow new opportunities to identify common
parameters in intragraft gene expression profiles in toler-
ant grafts. In addition, the development of accurate, tar-
geted and reliable tests for gene expression in graft
biopsies may someday be available for use in clinical
transplantation as a means to monitor graft survival.
Conclusion
In this study, we have described the intragraft gene expres-
sion changes that associate with the induction of toler-
ance to the αGal carbohydrate. Although the
cytoprotective genes HO-1, Bcl2 and A20 were not
induced in the early stages of tolerance induction in this
model, genes associated with stress and immunity were
up-regulated. This result suggests that the tolerant graft
itself responds on a continuous basis to the environment
around it. The reduction of αGal carbohydrate gene
expression over time in tolerant grafts indicates the possi-
bility of adaptation of the graft. An improved understand-
ing of the similarities and differences in intragraft gene
expression profiles that are associated with tolerance
induced by various approaches and a clear statement of
the methods used for the analysis of the data should allow
new opportunities to identify common parameters in
intragraft gene expression profiles in these grafts.BMC Immunology 2008, 9:5 http://www.biomedcentral.com/1471-2172/9/5
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Methods
Mice
Gal T-/- mice homozygous for the targeted disruption in
the GalT gene do not express the αGal epitope and pro-
duce anti-αGal-reactive antibodies in their serum. GalT-/-
mice were backcrossed 10 times using C57BL/6 mice
(Jackson Laboratory, Bar Harbor, ME) and were obtained
from Dr. A. d'Apice (St Vincent's Hospital in Melbourne,
Australia). The mice used for these experiments were 12 to
16 weeks age at the time of heart transplantation. All ani-
mals received humane care in compliance with the Princi-
ples of Laboratory Animal Care, formulated by the
National Society for Medical Research, and the Guide for
the Care and Use of Laboratory Animals, prepared by the
National Institutes of Health.
Transplantation of bone marrow cells transduced by 
lentiviral vectors
A nonmyeloablative regimen was used to establish chi-
merism by transplantation of bone marrow cells trans-
duced with a lentiviral vector expressing porcine α1,3
galactosyltransferase, as previously described [7]. Briefly,
bone marrow cells were flushed from the femurs of GalT-
/-  mice and were transduced with a lentiviral vector
expressing the porcine α1,3 GalT gene. Recipient mice
were matched for age and anti-αGal Ab levels prior to
bone marrow transplantation (BMT). Mice were suble-
thally irradiated with 3 Gy of whole-body irradiation
using a 137Cs irradiator. Transduced bone marrow cells
(2.7 × 107 to 5.0 × 107 cells) were administered by tail vein
injection to recipient GalT-/- mice within 48 hours after
irradiation.
Heterotopic heart transplantation
Intra-abdominal heterotopic heart transplantation was
performed at 2 to 4 weeks after BMT [46]. Heart grafts
from C57BL/6 mice were transplanted into GalT BMT
mice (n = 6), C57BL/6 syngeneic control mice (n = 8), and
GalT-/- mice that did not receive a BMT to induce chimer-
ism (n = 6). Mice were anesthetized with 1.5 to 2.0% Iso-
flurane. The heart grafts from C57BL/6 mice which were
transplanted to GalT-/- mice in the absence of a BMT to
achieve chimerism were rejected at an average of 12.8 days
after transplantation. Graft function was monitored daily
by palpation. At day 10 post heart transplantation, recipi-
ent mice were euthanized for examination. Tolerance at
early and late time points was compared by isolation of
hearts at Day 10 (n = 6) and at >2 months post-heart
transplantation (n = 3). Matched syngeneic control mice
were examined at early and late time points (n = 8, n = 3
each). The RNA was extracted from the graft tissue and
microarray data were used to compare gene expression at
the early and later time points.
RNA extraction from heart graft samples
The graft heart tissues for RNA extraction were immedi-
ately frozen and kept at -80°C. RNA was isolated and
purified using an RNeasy Fibrous Tissue Mini Kit (Qiagen,
Valencia, CA) according to manufacturer's instructions.
Optical density was measured by spectrophotometry at
260 and 280 nm, and integrity of total RNA was con-
firmed by agarose gel electrophoresis.
Microarray target preparation and hybridization for 
Affymetrix GeneChips
Affymetrix GeneChip Mouse 430 2.0 Expression Arrays
were used for this study. Two μg of tRNA was reverse tran-
scribed using a T7-Oligo(dT) primer. Second-strand
cDNA was purified and used as a template for in vitro tran-
scription (IVT). IVT with T7 RNA Polymerase and biotin
yielded labeled cRNA targets that were then fragmented
and 10 μg hybridized to the GeneChip. These procedures
were performed by the USC/CHLA Genome Core, Depart-
ment of Pathology, Childrens Hospital Los Angeles
according to the manufacturer's protocol (Affymetrix,
Santa Clara, CA).
Microarray data analysis
The processed image file of the Affymetrix Mouse 430v2
array contained over 45000 probe sets covering approxi-
mately 39000/34000 transcripts/genes [47]. The probe set
level data were analyzed with the dChip software [48].
Values deemed "present' using the PM/MM correction
model with single probe rejection were considered fur-
ther. The algorithm "Significant Analysis of Microarrays
(SAM)" which uses a permutation test to set the "no-
change" expression threshold, selecting genes that
showed statistically significant differences for each condi-
tion. The program generated a false positive rate or a q-
value for each gene for the replicated samples using a
nearest neighbor metric. This test creates a set of individ-
ual genes that are differentially expressed for each ligand-
time condition. To note the enrichment of a particular
gene annotation from the list of differentially expressed
genes determined to be statistically significant (p < 0.01),
we used the hypergeometric distribution formula. The
gene ontology was obtained from the L2L database [49].
We selected the gene attribute "biological process" as
described by the Gene Ontology Consortium [50] for sub-
group enrichment. We elected to use dChip, SAM, and
L2L software packages as they are available free of charge
to facilitate the comparison of our data with that obtained
by other investigators interested in the identification of
genes expressed in tolerant grafts. The microarray data
used in this study was deposited in the National Center
for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) [51] with accession numbers
GSM179880 through GSM 179573. The microarray dataBMC Immunology 2008, 9:5 http://www.biomedcentral.com/1471-2172/9/5
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are also available in a series with accession number GSE
7424.
Quantitative real-time PCR
Total RNA was reverse-transcribed into cDNA (Omnis-
cript RT Kit, Qiagen, Valencia, CA). Quantitative real-time
PCR was performed using an ABI PRISM 7700 Sequence
Detector (Perkin Elmer, Foster City, CA) and a Quantitect
SYBR Green PCR Kit (Qiagen, Valencia, CA) according to
manufacturer's protocol. PCR amplification was per-
formed at 95°C for 15 min followed by 45 cycles of 95°C
for 15 sec, 56°C for 30 sec, and 72°C for 30 sec. Each PCR
was performed in triplicate. Samples were electro-
phoresed on a 1.5% agarose gel to confirm that nonspe-
cific amplification did not occur. Results were expressed
relative to the housekeeping gene, glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH). Oligonucleotides used
as primers in this study are shown in Table 3.
List of abbreviations
All abbreviations are defined at their first appearance in
the text, and in the legends of tables and figures, as fol-
lows:
αGal – Galα1,3Galβ1,4GlcNac-R
GalT – α1,3 galactosyltransferase
GalT-/- – gal knockout
NF-κB – nuclearfactor kappa B
BMT – bone marrow transplantation
HO-1 – heme oxygenase-1
SAM – significant analysis of microarrays
Gene Ontology – GO
IVT – in vitro transcription
NCBI – National Center for Biotechnology Information
GEO – Gene Expression Omnibus
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